Jay Paul Reddy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2097266/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Contemporary Outcomes After Multimodality Therapy in Patients With Breast Cancer Presenting With Ipsilateral Supraclavicular Node Involvement. International Journal of Radiation Oncology Biology Physics, 2022, 112, 66-74.	0.4	9
2	Adoption of Ultrahypofractionated Radiation Therapy in Patients With Breast Cancer. Advances in Radiation Oncology, 2022, 7, 100877.	0.6	4
3	Unilateral Radiotherapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papilloma Virus (HPV), Positron-emission Tomography (PET) and Intensity-modulated Radiation Therapy (IMRT). International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	6
4	Development and validation of a contouring guideline for the taste bud bearing tongue mucosa. Radiotherapy and Oncology, 2021, 157, 63-69.	0.3	4
5	Longitudinal characterization of the tumoral microbiome during radiotherapy in HPV-associated oropharynx cancer. Clinical and Translational Radiation Oncology, 2021, 26, 98-103.	0.9	7
6	Defining the doseâ€volume criteria for laryngeal sparing in locally advanced oropharyngeal cancer utilizing splitâ€field IMRT, wholeâ€field IMRT and VMAT. Journal of Applied Clinical Medical Physics, 2021, 22, 37-44.	0.8	3
7	Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. Oral Oncology, 2021, 113, 105125.	0.8	12
8	Proton Therapy for Major Salivary Gland Cancer: Clinical Outcomes. International Journal of Particle Therapy, 2021, 8, 261-272.	0.9	4
9	Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy. Current Treatment Options in Oncology, 2021, 22, 54.	1.3	11
10	Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. International Journal of Particle Therapy, 2021, 8, 108-118.	0.9	8
11	Work Outcomes after Intensity-Modulated Proton Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for Oropharyngeal Cancer. International Journal of Particle Therapy, 2021, 8, 319-327.	0.9	11
12	Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, singleâ€institution, modern cohort study. Head and Neck, 2021, 43, 3331-3344.	0.9	15
13	Estimating PTV Margins in Head and Neck Stereotactic Ablative Radiation Therapy (SABR) Through Target Site Analysis of Positioning and Intrafractional Accuracy. International Journal of Radiation Oncology Biology Physics, 2020, 106, 185-193.	0.4	12
14	Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy. Journal of Neurological Surgery, Part B: Skull Base, 2020, 81, 638-644.	0.4	7
15	A prospective evaluation of healthâ€related quality of life after skull base reâ€irradiation. Head and Neck, 2020, 42, 485-497.	0.9	3
16	Outcomes and patterns of radiation associated brain image changes after proton therapy for head and neck skull base cancers. Radiotherapy and Oncology, 2020, 151, 119-125.	0.3	10
17	The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors. Clinical and Translational Radiation Oncology, 2020, 24, 71-78.	0.9	11
18	<pre><scp>Highly conformal</scp> reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. Head and Neck, 2020, 42, 3326-3335.</pre>	0.9	14

JAY PAUL REDDY

#	Article	IF	CITATIONS
19	A Dosimetric Comparison of Oral Cavity Sparing in the Unilateral Treatment of Early Stage Tonsil Cancer: IMRT, IMPT, and Tongue-Deviating Oral Stents. Advances in Radiation Oncology, 2020, 5, 1359-1363.	0.6	7
20	Comparison of tumor delineation using dual energy computed tomography versus magnetic resonance imaging in head and neck cancer re-irradiation cases. Physics and Imaging in Radiation Oncology, 2020, 14, 1-5.	1.2	9
21	Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. Radiotherapy and Oncology, 2020, 148, 258-266.	0.3	21
22	Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: Potential for improvement over time?. Clinical and Translational Radiation Oncology, 2020, 22, 98-105.	0.9	5
23	Quantitative 3-Dimensional Photographic Assessment of Breast Cosmesis After Whole Breast Irradiation for Early Stage Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. Advances in Radiation Oncology, 2020, 5, 824-833.	0.6	7
24	Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. Radiotherapy and Oncology, 2020, 148, 133-139.	0.3	11
25	SABR for Skull Base Malignancies: A Systematic Analysis of Set-Up and Positioning Accuracy. Practical Radiation Oncology, 2020, 10, 363-371.	1.1	3
26	Radiation Therapy Complications Leading to Critical Illness. , 2020, , 1547-1554.		0
27	Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. Radiotherapy and Oncology, 2019, 131, 88-92.	0.3	6
28	Optimizing laryngeal sparing with intensity modulated radiotherapy or volumetric modulated arc therapy for unilateral tonsil cancer. Physics and Imaging in Radiation Oncology, 2019, 10, 29-34.	1.2	2
29	Postoperative Radiation Therapy for Metastatic Cervical Adenopathy. Seminars in Radiation Oncology, 2019, 29, 144-149.	1.0	2
30	Intensity modulated proton therapy (IMPT) – The future of IMRT for head and neck cancer. Oral Oncology, 2019, 88, 66-74.	0.8	103
31	Radiographic retropharyngeal lymph node involvement in HPVâ€associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes. Cancer, 2019, 125, 1536-1546.	2.0	19
32	Preâ€ŧreatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. British Journal of Haematology, 2018, 180, 545-549.	1.2	38
33	Cost Analysis of PET/CT Versus CT as Surveillance for Stage III Non–Small-Cell Lung Cancer After Definitive Radiation Therapy. Clinical Lung Cancer, 2018, 19, e517-e528.	1.1	6
34	Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood, 2018, 131, 84-94.	0.6	78
35	Implementing an Electronic Data Capture System to Improve Clinical Workflow in a Large Academic Radiation Oncology Practice. JCO Clinical Cancer Informatics, 2018, 2, 1-12.	1.0	14
36	Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer. Breast Cancer Research and Treatment, 2018, 171, 283-293.	1.1	15

JAY PAUL REDDY

#	Article	IF	CITATIONS
37	Gene set analysis of post-lactational mammary gland involution gene signatures in inflammatory and triple-negative breast cancer. PLoS ONE, 2018, 13, e0192689.	1.1	20
38	Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2017, 58, 2833-2844.	0.6	13
39	Quantitative Assessment of Breast Cosmetic Outcome After Whole-Breast Irradiation. International Journal of Radiation Oncology Biology Physics, 2017, 97, 894-902.	0.4	9
40	Earlyâ€stage Hodgkin lymphoma outcomes after combined modality therapy according to the postâ€chemotherapy 5â€point score: can residual petâ€positive disease be cured with radiotherapy alone?. British Journal of Haematology, 2017, 179, 488-496.	1.2	9
41	Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. International Journal of Radiation Oncology Biology Physics, 2017, 97, 333-338.	0.4	10
42	Factors associated with regional recurrence after lymph node dissection for penile squamous cell carcinoma. BJU International, 2017, 119, 591-597.	1.3	15
43	Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non–small-cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 141-148.	1.1	12
44	Lack of Breastfeeding History in Parous Women with Inflammatory Breast Cancer Predicts Poor Disease-Free Survival. Journal of Cancer, 2017, 8, 1726-1732.	1.2	5
45	Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation. International Journal of Radiation Oncology Biology Physics, 2016, 96, 110-118.	0.4	9
46	MiR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity inÂBreast Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 791-799.	0.4	21
47	Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy. Leukemia and Lymphoma, 2016, 57, 34-38.	0.6	34
48	Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma. Radiation Oncology, 2015, 10, 206.	1.2	1
49	Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2015, 92, 175-182.	0.4	110
50	High-Density and Very-Low-Density LipoproteinÂHave Opposing Roles in Regulating Tumor-Initiating Cells and Sensitivity to Radiation in Inflammatory Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 91, 1072-1080.	0.4	33
51	Antiepileptic drug use improves overall survival in breast cancer patients with brain metastases in the setting of whole brain radiotherapy. Radiotherapy and Oncology, 2015, 117, 308-314.	0.3	23
52	Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 664-670.e2.	0.2	4
53	Simvastatin Radiosensitizes Differentiated and Stem-Like Breast Cancer Cell Lines and Is Associated With Improved Local Control in Inflammatory Breast Cancer Patients Treated With Postmastectomy Radiation. Stem Cells Translational Medicine, 2014, 3, 849-856.	1.6	69
54	Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy. ELife, 2013, 2, e00996.	2.8	42

JAY PAUL REDDY

#	Article	IF	CITATIONS
55	In Reply to Drs. Pergolizzi and Santacaterina. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1059.	0.4	0
56	Oncogene-Induced Senescence and its Role in Tumor Suppression. Journal of Mammary Gland Biology and Neoplasia, 2011, 16, 247-256.	1.0	15
57	Long-Term Outcomes in Patients With Isolated Supraclavicular Nodal Recurrence After Mastectomy and Doxorubicin-Based Chemotherapy for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1453-1457.	0.4	20
58	Defining the ATM-mediated barrier to tumorigenesis in somatic mammary cells following ErbB2 activation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3728-3733.	3.3	53
59	The RCAS-TVA System for Introduction of Oncogenes into Selected Somatic Mammary Epithelial Cells in Vivo. Journal of Mammary Gland Biology and Neoplasia, 2009, 14, 405-409.	1.0	15